Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular

of the first publication of the final draft guidance. 5.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if the healthcare professional responsible for the care of a patient thinks that clopidogrel and modified-release dipyridamole is the right treatment for the prevention of occlusive vascular events, it should be available for use, in line with NICE's recommendations.
